Amarin Corp PLC (NASDAQ:AMRN) Sentiment Improved, Because

Amarin Corporation plc (NASDAQ:AMRN) Logo

Sentiment for Amarin Corp PLC (NASDAQ:AMRN)

Amarin Corp PLC (NASDAQ:AMRN) institutional sentiment increased to 1.44 in 2018 Q2. Its up 0.39, from 1.05 in 2018Q1. The ratio has improved, as 49 active investment managers opened new and increased positions, while 34 decreased and sold stock positions in Amarin Corp PLC. The active investment managers in our partner’s database now hold: 101.63 million shares, down from 113.30 million shares in 2018Q1. Also, the number of active investment managers holding Amarin Corp PLC in their top 10 positions decreased from 3 to 2 for a decrease of 1. Sold All: 19 Reduced: 15 Increased: 34 New Position: 15.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company has market cap of $5.46 billion. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

The stock decreased 6.00% or $1.08 during the last trading session, reaching $16.91. About 5.76 million shares traded. Amarin Corporation plc (NASDAQ:AMRN) has declined 3.76% since December 8, 2017 and is downtrending. It has underperformed by 19.38% the S&P500.

Analysts await Amarin Corporation plc (NASDAQ:AMRN) to report earnings on February, 26. They expect $-0.10 EPS, down 25.00 % or $0.02 from last year’s $-0.08 per share. After $-0.08 actual EPS reported by Amarin Corporation plc for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.

Healthcare Value Capital Llc holds 4.38% of its portfolio in Amarin Corporation plc for 500,000 shares. Oracle Investment Management Inc owns 5.26 million shares or 3.93% of their US portfolio. Moreover, Opaleye Management Inc. has 1.4% invested in the company for 1.75 million shares. The New York-based Consonance Capital Management Lp has invested 0.99% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 22.67 million shares.

Since January 1, 0001, it had 0 insider buys, and 12 selling transactions for $35.91 million activity.

Amarin Corporation plc (NASDAQ:AMRN) Ratings Coverage

Ratings analysis reveals 50% of Amarin Corp’s analysts are positive. Out of 2 Wall Street analysts rating Amarin Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $15 while the high is $28. The stock’s average target of $21.50 is 27.14% above today’s ($16.91) share price. AMRN was included in 4 notes of analysts from September 25, 2018. The stock of Amarin Corporation plc (NASDAQ:AMRN) has “Neutral” rating given on Friday, November 2 by Citigroup. The stock has “Buy” rating by Citigroup on Tuesday, September 25. The stock of Amarin Corporation plc (NASDAQ:AMRN) earned “Buy” rating by Citigroup on Wednesday, October 17. The stock of Amarin Corporation plc (NASDAQ:AMRN) has “Buy” rating given on Tuesday, September 25 by Jefferies.

More notable recent Amarin Corporation plc (NASDAQ:AMRN) news were published by: Seekingalpha.com which released: “Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released – Seeking Alpha” on November 12, 2018, also Nasdaq.com with their article: “Amarin Prices Public Offering of American Depositary Shares – Nasdaq” published on November 26, 2018, Prnewswire.com published: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation – AMRN – PRNewswire” on November 13, 2018. More interesting news about Amarin Corporation plc (NASDAQ:AMRN) were released by: Seekingalpha.com and their article: “Amarin’s REDUCE-IT Trial: Something Fishy? – Seeking Alpha” published on November 11, 2018 as well as Nasdaq.com‘s news article titled: “Amarin (AMRN) Beats Earnings & Misses Revenues in Q3 – Nasdaq” with publication date: November 01, 2018.

Amarin Corporation plc (NASDAQ:AMRN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.